Prostate-specific antigen bounce after curative brachytherapy for early-stage prostate cancer: A study of 274 African-Caribbean patients
| Autor: | Patrick Escarmant, Vincent Vinh-Hung, V. Atallah, T. Taouil, M. Creoff, N. Leduc, N. Rabia |
|---|---|
| Přispěvatelé: | Radiation Therapy, Translational Radiation Oncology and Physics, Faculty of Medicine and Pharmacy |
| Rok vydání: | 2015 |
| Předmět: |
Male
medicine.medical_specialty Time Factors Stage prostate cancer AFRICAN CARIBBEAN medicine.medical_treatment Brachytherapy Population Urology Black People urologic and male genital diseases Iodine Radioisotopes Androgen deprivation therapy Prostate cancer medicine Humans Radiology Nuclear Medicine and imaging education African-Caribbean Aged Gynecology education.field_of_study business.industry Age Factors Prostatic Neoplasms Androgen Antagonists Middle Aged Prostate-Specific Antigen PSA bounce medicine.disease Prostate-specific antigen Caribbean Region Oncology Radiology Nuclear Medicine and imaging business Follow-Up Studies |
| Zdroj: | Brachytherapy. 14:826-833 |
| ISSN: | 1538-4721 |
| DOI: | 10.1016/j.brachy.2015.09.005 |
| Popis: | Background: Prostate cancer incidence in the African-Caribbean population ranks among the highest worldwide. We aim to evaluate the prostate-specific antigen (PSA) kinetics after brachytherapy, which so far remains unknown in this population. Methods and Materials: From 2005 to 2013, 371 patients received 125I brachytherapy of 145 Gy for early-stage prostate cancer. Eligibility criteria were cTNM ≤T2c, Gleason score ≤7, and initial PSA ≤15 ng/mL. Pretreatment androgen deprivation therapy was allowed. PSA bounce was defined as an increase of ≥0.4 ng/mL, lasting ≥6 months, followed by a decrease without any anticancer therapy. We examined PSA kinetics during followup. Results: For the 274 patients with at least 24 months followup, median age was 62 years old (range, 45-76). Initial PSA was |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|